Herbert T Nagasawa
Overview
Explore the profile of Herbert T Nagasawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crankshaw D, Briggs J, Vince R, Nagasawa H
Antioxidants (Basel)
. 2021 Jul;
10(6).
PMID: 34200599
L-Cysteine-glutathione mixed disulfide (CySSG), a prodrug of glutathione (GSH), was found to be orally bioavailable in mice, and protected mice against a toxic dose of acetaminophen. If oral bioavailability can...
2.
Nagasawa H, Valentekovich R, Nagasawa S, Nagasawa R
Chem Res Toxicol
. 2020 Jan;
33(3):764-768.
PMID: 31989817
It is well-known that aldehydes resulting from the oxidation of primary alcohols are toxic. Here, we experimentally demonstrate in rat models that the dipeptide cysteinylglycine (CG), formed from its oxidized...
3.
Moeller B, Crankshaw D, Briggs J, Nagasawa H, Patterson S
Toxicol Lett
. 2017 Apr;
274:64-68.
PMID: 28412453
Cyanide is a metabolic poison that inhibits cytochrome c oxidase. Its broad applications in manufacturing and history as an agent of warfare/terror highlight the limitations in approved cyanide antidotes for...
4.
Patterson S, Moeller B, Nagasawa H, Vince R, Crankshaw D, Briggs J, et al.
Ann N Y Acad Sci
. 2016 Jun;
1374(1):202-9.
PMID: 27308865
Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and...
5.
Patterson S, Monteil A, Cohen J, Crankshaw D, Vince R, Nagasawa H
J Med Chem
. 2013 Jan;
56(3):1346-9.
PMID: 23301495
Current cyanide antidotes are administered by IV infusion, which is suboptimal for mass casualties. Therefore, in a cyanide disaster, intramuscular (IM) injectable antidotes would be more appropriate. We report the...
6.
Belani K, Singh H, Beebe D, George P, Patterson S, Nagasawa H, et al.
Anesth Analg
. 2012 Mar;
114(5):956-61.
PMID: 22392971
Background: Cyanide (CN) toxicity is a serious clinical problem and can occur with sodium nitroprusside (SNP) administration, accidental smoke inhalation, industrial mishaps, and bio-terrorism. In this study, we induced severe...
7.
Chan A, Crankshaw D, Monteil A, Patterson S, Nagasawa H, Briggs J, et al.
Clin Toxicol (Phila)
. 2011 Jul;
49(5):366-73.
PMID: 21740135
Context: Cyanide is a component of smoke in residential and industrial fires, and accidental exposure to cyanide occurs in a variety of industries. Moreover, cyanide has the potential to be...
8.
Brenner M, Kim J, Lee J, Mahon S, Lemor D, Ahdout R, et al.
Toxicol Appl Pharmacol
. 2010 Aug;
248(3):269-76.
PMID: 20705081
The aim of this study is to investigate the ability of intramuscular and intravenous sulfanegen sodium treatment to reverse cyanide effects in a rabbit model as a potential treatment for...
9.
Nagasawa H, Goon D, Crankshaw D, Vince R, Patterson S
J Med Chem
. 2007 Nov;
50(26):6462-4.
PMID: 18038966
A series of prodrugs of 3-mercaptopyruvate (3-MP), the substrate for the enzyme 3-mercaptopyruvate/cyanide sulfurtransferase (3-MPST) that converts cyanide to the nontoxic thiocyanate, which are highly effective cyanide antidotes, have been...
10.
Crankshaw D, Goon D, Briggs J, DeLong D, Kuskowski M, Patterson S, et al.
Toxicol Lett
. 2007 Nov;
175(1-3):111-7.
PMID: 18024011
Historically, antidotal potencies of cyanide antagonists were measured as increases in the experimental LD(50) for cyanide elicited by the antidotes. This required the use of high doses of cyanide following...